In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 271 to 280 of 372

TitleTypeExpected publication date
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]Technology appraisal guidance
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Renal sympathetic denervation for resistant hypertensionHealthTech guidanceTBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]Technology appraisal guidanceTBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]Technology appraisal guidanceTBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]Technology appraisal guidance
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]Technology appraisal guidanceTBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All